Enoxaparin may be safe for patients with cancer, brain metastases
the ONA take:
According to a new study published online in the journal Blood, researchers have found that patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin, a type of low molecular weight heparin anticoagulant, without increased risk of intracranial hemorrhage.
For the study, researchers sought to assess the risk of intracranial hemorrhage, a dangerous form of bleeding in the head, associated with the administration of therapeutic doses of enoxaparin.
Researchers identified 239 patients with cancer and brain metastases. Of those, 104 received therapeutic enoxaparin and 189 were their matched controls that did not receive blood-thinning treatment.
Results showed that there were no differences in the cumulative incidence of intracranial hemorrhage at 1 year in the enoxaparin and control cohorts.
Researchers found that patients with melanoma or renal cell carcinoma had a fourfold higher risk of intracranial hemorrhage than those with lung cancer, but administration of enoxaparin did not affect that risk. The study also showed that overall survival was similar in both groups.
Patients with cancer and brain metastases who develop blood clots may safely receive enoxaparin.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|